Roche Holding AG
RHO6
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
103,249
Stocks News & Analysis
stocks
Why I dislike dividend stocks
If you need income then buying dividend stocks makes perfect sense. But if you don’t then it makes little sense because it’s likely to limit building real wealth. Here’s what you should do instead.
stocks
Chart of the Week: Ramsay Health Care margins to rebound
Charts from our latest stock pitch for Ramsay Health Care show a clear path to improved profitability.
stocks
BlackRock earnings: Market gains and inflows drive AUM and revenue to record highs
We plan to raise our fair value estimate of BlackRock stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,375.90 | 19.70 | 0.21% |
CAC 40 | 8,077.00 | 157.38 | 1.99% |
DAX 40 | 24,181.37 | 55.57 | -0.23% |
Dow JONES (US) | 46,253.31 | 17.15 | -0.04% |
FTSE 100 | 9,424.75 | 28.02 | -0.30% |
HKSE | 25,722.65 | 187.95 | -0.73% |
NASDAQ | 22,670.08 | 148.38 | 0.66% |
Nikkei 225 | 48,246.69 | 574.02 | 1.20% |
NZX 50 Index | 13,389.10 | 81.70 | 0.61% |
S&P 500 | 6,671.06 | 26.75 | 0.40% |
S&P/ASX 200 | 9,068.40 | 18.20 | 0.20% |
SSE Composite Index | 3,902.70 | 9.51 | -0.24% |